Implementation Research on Hypertension Control to Prevent Dementia and Cognitive Decline (R61/R33 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials on dissemination and implementation of practical approaches to hypertension treatment and control strategies among older adults with multimorbidity in order to prevent sequelae, including mild cognitive impairment and dementia. The research will: (1) be designed to address practical hypertension treatment questions faced by older adults with multimorbidity and their clinicians, (2) include broad and diverse populations, and (3) be conducted in real-world settings. These trials are intended to produce results that can be directly adopted by healthcare systems for rapid translation.

This FOA will support pilot research to test the feasibility of implementing care interventions (R61 phase) that, if successful, can transition to an R33 phase for implementation of large pragmatic trials. 

The transition from the R61 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the go/no-go criteria that are specified for the R61 phase. 



  • Letter of Intent Due Date(s): September 22, 2019
  • Application Due Date(s): October 22, 2019

​RFA-AG-20-028 Expiration Date October 23, 2019

Agency Website

Amount Description

For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed $500,000.

For the R33 phase, budgets may go over $500,000.

The project period is limited to 5 years, which includes up to 2 years of the R61 phase, followed by up to 4 years of the R33 phase. 

Funding Type





Medical - Clinical Science

External Deadline

October 22, 2019